Search Result

Pathways Recommended:	Metabolic Enzyme/Protease

Results for "

myocardial enzyme

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Angiotensin-converting Enzyme (ACE) (12) Autophagy (1) Drug Metabolite (1) Epoxide Hydrolase (1) Guanylate Cyclase (1) Isotope-Labeled Compounds (3) Legumain (1) Na+/H+ Exchanger (NHE) (2) Neprilysin (1) Reference Standards (2) SGLT (1) SOD (1) Sodium Channel (1)
By Research Areas:	Cancer (1) Cardiovascular Disease (17)

Inhibitors & Agonists

Screening Libraries

Isotope-Labeled Compounds

Targets Recommended: Peroxidase Enzyme Proteolytic Enzyme Carnosine-cleaving Enzyme Endothelin-Converting Enzyme (ECE) Angiotensin-converting Enzyme (ACE) NEDD8-activating Enzyme E1/E2/E3 Enzyme IDE IRE1 TET Protein

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0384

Temocapril hydrochloride 2 Publications Verification	Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Temocapril hydrochloride is an orally active angiotensin-converting enzyme (ACE) inhibitor. Temocapril hydrochloride can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases .

HY-100713

Temocapril 2 Publications Verification	Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Temocapril is an orally active angiotensin-converting enzyme (ACE) inhibitor. Temocapril can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases .

HY-112205

RR-11a 2 Publications Verification	Legumain	Cancer
RR-11a is a synthetic enzyme inhibitor of Legumain (IC₅₀=31-55 nM). RR-11a can be used for the research of cancer and acute myocardial infarction (AMI) .

HY-B0592

Trandolapril RU44570	Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .

HY-19862

TY-51924 ethanol sodium	Na+/H+ Exchanger (NHE)	Cardiovascular Disease
TY-51924 (ethanol sodium) is a highly selective NHE-1 inhibitor (IC₅₀ = 0.095 μM). TY-51924 (ethanol sodium) can significantly reduce the infarct size and myocardial enzyme release. TY-51924 (ethanol sodium) is commonly used in the study of ischemia-reperfusion injury .

HY-100713R

Temocapril (Standard)	Reference Standards Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Temocapril (Standard) is the analytical standard of Temocapril. This product is intended for research and analytical applications. Temocapril is an orally active angiotensin-converting enzyme (ACE) inhibitor. Temocapril can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases .

HY-B0384R

Temocapril hydrochloride (Standard)	Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Temocapril (hydrochloride) (Standard) is the analytical standard of Temocapril (hydrochloride). This product is intended for research and analytical applications. Temocapril hydrochloride is an orally active angiotensin-converting enzyme (ACE) inhibitor. Temocapril hydrochloride can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases .

HY-100713S

Temocapril-d5	Isotope-Labeled Compounds Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Temocapril-d₅ is the deuterium labeled Temocapril. Temocapril is an angiotensin-converting enzyme (ACE) inhibitor. Temocapril hydrochloride can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases .

HY-W803860

N-Depropylpropafenone	Drug Metabolite Sodium Channel	Cardiovascular Disease
N-Depropylpropafenone is an active metabolite of Propafenone (HY-B0432), generated through the CYP450 enzyme system (mainly CYP2D6). It functions by blocking sodium ion channels, slowing myocardial conduction and exhibiting certain antiarrhythmic effects .

HY-114941

Aladotril BP1137	Angiotensin-converting Enzyme (ACE) Neprilysin	Cardiovascular Disease
Aladotril (BP1137) is the inhibitor for neutral endopeptidase (NEP) and *angiotensin-converting enzyme* (ACE)*, that ameliorates the cardiac hypertrophy in rats, without decreasing the blood pressure. Aladotril can be used in research about heart failure and cardiac remodeling after myocardial* infarction .

HY-B0592A

Trandolapril hydrochloride RU44570 hydrochloride	Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Trandolapril (RU44570) hydrochloride is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolapril hydrochlorideat. Trandolapril hydrochloride is an orally active angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .

HY-B0592R

Trandolapril (Standard) RU44570 (Standard)	Reference Standards Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Trandolapril (Standard) is the analytical standard of Trandolapril. This product is intended for research and analytical applications. Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .

HY-143294

sEH inhibitor-2	Epoxide Hydrolase	Cardiovascular Disease
sEH inhibitor-2 (compound 5l) is an orally active (predicted percentage absorption: 71.2-88.4%) soluble epoxide hydrolase (sEH) inhibitor, with an IC₅₀ of 0.9 nM. sEH inhibitor-2 can maintain epoxyeicosatrienoic acids (EETs) serum level in high concentrations. sEH inhibitor-2 can be used in study of cardiovascular protection .

HY-W744298

Trandolapril-d3	Isotope-Labeled Compounds Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Trandolapril-d₃ is the deuterium labeled Trandolapril (HY-B0592). Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .

HY-A0113

Cilazaprilat Ro 31-3113	Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Cilazaprilat is an inhibitor of angiotensin-converting enzyme (ACE; IC₅₀=0.7 nM for the rat enzyme) and an active metabolite of Cilazapril (HY-A0043). It decreases creatine kinase release in primary neonatal rat cardiac myocytes in an in vitro model of ischemia-reperfusion injury induced by hypoxia and reoxygenation when used at a concentration of 10 μM.3 Intra-arterial administration of cilazaprilat (3 μg/kg per minute) increases coronary blood flow and fractional shortening in a dog model of coronary hypoperfusion-induced myocardial ischemia.

HY-B0592S2

rac-Trandolapril-d5 rac-RU44570-d₅	Isotope-Labeled Compounds Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
rac-Trandolapril-d₅ (rac-RU44570-d₅) is deuterium labeled Trandolapril. Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .

HY-142698

SGC agonist 2	Guanylate Cyclase	Cardiovascular Disease
SGC agonist 2 is a potent agonist of soluble guanylate cyclase (SGC). Soluble guanylate cyclase is a key signal transduction enzyme in the NO-sGC-cGMP signaling pathway. SGC agonist 2 has the potential for the research of cardiovascular disease (heart failure, pulmonary hypertension, angina, myocardial infarction) and fibrotic diseases (renal fibrosis, systemic sclerosis) (extracted from patent WO2021219088A1, compound 031) .

HY-174400

SGLT2-IN-2	SGLT SOD Na+/H+ Exchanger (NHE) Autophagy	Cardiovascular Disease
SGLT2-IN-2 (Compound E9) is an inhibitor of SGLT2. SGLT2-IN-2 significantly enhances the inhibition of SGLT2, NHE1, and SOD enzyme activity. SGLT2-IN-2 has protective effect on the glucose-free DMEM-induced injured cardiomyocytes. SGLT2-IN-2 significantly improves cardiac function in TAC-induced HF mice and inhibits cardiomyocyte hypertrophy as well as collagen deposition. SGLT2-IN-2 can ameliorate myocardial tissue damage and enhance mitochondrial autophagy in injured cardiomyocytes, thereby increasing survival rates in HF mice .

Cat. No.	Product Name

HY-L046

Anti-Cardiovascular Disease Compound Library	2,060 compounds
Cardiovascular diseases (CVDs) are a group of disorders of the heart and blood vessels which include coronary heart disease, cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, etc. CVDs are the number 1 cause of death globally. Smoking, unhealthy nutrition, aging population, lack of physical activity, arterial hypertension, or diabetes can promote cardiovascular disease like myocardial infarction or stroke. It is multifactorial and encompasses a multitude of mechanisms, such as eNOS uncoupling, reactive oxygen species formation, chronic inflammatory disorders and abnormal calcium homeostasis. Antioxidant, anti-inflammatory and anti-diabetes agents may reduce the cardiovascular disease risk. MCE supplies a unique collection of 2,060 compounds with confirmed anti-cardiovascular activity. These compounds mainly target metabolic enzyme, membrane transporter, ion channel, inflammation related signaling pathways. MCE Anti-Cardiovascular Disease Compound Library can be used for cardiovascular diseases related research and high throughput and high content screening for new drugs.

Anti-Cardiovascular Disease Compound Library

2,060 compounds

Cardiovascular diseases (CVDs) are a group of disorders of the heart and blood vessels which include coronary heart disease, cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, etc. CVDs are the number 1 cause of death globally. Smoking, unhealthy nutrition, aging population, lack of physical activity, arterial hypertension, or diabetes can promote cardiovascular disease like myocardial infarction or stroke. It is multifactorial and encompasses a multitude of mechanisms, such as eNOS uncoupling, reactive oxygen species formation, chronic inflammatory disorders and abnormal calcium homeostasis. Antioxidant, anti-inflammatory and anti-diabetes agents may reduce the cardiovascular disease risk.

MCE supplies a unique collection of 2,060 compounds with confirmed anti-cardiovascular activity. These compounds mainly target metabolic enzyme, membrane transporter, ion channel, inflammation related signaling pathways. MCE Anti-Cardiovascular Disease Compound Library can be used for cardiovascular diseases related research and high throughput and high content screening for new drugs.

Cat. No.	Product Name	Chemical Structure

HY-100713S

Temocapril-d5
Temocapril-d₅ is the deuterium labeled Temocapril. Temocapril is an angiotensin-converting enzyme (ACE) inhibitor. Temocapril hydrochloride can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases .

HY-W744298

Trandolapril-d3
Trandolapril-d₃ is the deuterium labeled Trandolapril (HY-B0592). Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .

HY-B0592S2

rac-Trandolapril-d5
rac-Trandolapril-d₅ (rac-RU44570-d₅) is deuterium labeled Trandolapril. Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .

rac-Trandolapril-d5

rac-Trandolapril-d₅ (rac-RU44570-d₅) is deuterium labeled Trandolapril. Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.